Is It Too Late To Consider BrightSpring Health Services (BTSG) After Its 185% One-Year Rally?

• Wondering whether BrightSpring Health Services at US$47.27 is still offering value after a strong run? This article breaks down what that price could mean for you.
• The stock has posted returns of 4.3% over the last 7 days, 14.7% over 30 days, 23.1% year to date and 184.8% over the past year, which has put valuation questions firmly on the table.
• Recent coverage has focused on BrightSpring’s position within the healthcare sector and investor interest around its public listing and business model. This helps explain why the stock has been on many watchlists and provides useful context as you weigh whether the current share price still lines up with the underlying business.
• Simply Wall St currently gives BrightSpring a value score of 2 out of 6. Next, you will see how different valuation approaches assess the stock, followed by a way to frame those numbers that can be even more useful for long term decisions.

BrightSpring Health Services scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: BrightSpring Health Services Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today’s value using a required return, giving an estimate of what the whole business could be worth per share.

For BrightSpring Health Services, the model starts with last twelve months Free Cash Flow of about $385 million. Analyst and extrapolated projections suggest FCF reaching about $1,009.7 million in 2030, with intermediate annual figures between these two points. Simply Wall St uses a 2 Stage Free Cash Flow to Equity approach, where analysts supply estimates for the nearer years and later years are extrapolated.

On this basis, the DCF output points to an estimated intrinsic value of about $146.40 per share. Compared with the current share price of $47.27, this implies the stock is trading at roughly a 67.7% discount to that DCF estimate. This indicates a wide gap between the modelled value and the market price.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests BrightSpring Health Services is undervalued by 67.7%. Track this in your watchlist or portfolio, or discover 60 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for BrightSpring Health Services.

Approach 2: BrightSpring Health Services Price vs Earnings (P/E)

For a profitable company, the P/E ratio is a straightforward way to think about what you are paying for each dollar of earnings. This is why it tends to be a preferred yardstick for many investors.

What counts as a reasonable P/E depends a lot on how quickly earnings are expected to grow and how risky those earnings are. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually points to a lower, more conservative multiple.

BrightSpring currently trades on a P/E of 91.07x, compared with a Healthcare industry average of 23.49x and a peer group average of 26.53x. Simply Wall St’s Fair Ratio for BrightSpring is 32.56x. This Fair Ratio is a proprietary view of what the P/E might be, given factors such as earnings growth profile, profit margins, industry, market cap and key risks.

Because the Fair Ratio blends these fundamentals into a single benchmark, it can be more informative than simply lining the stock up against broad industry or peer averages that may not share the same growth or risk profile.

Here, BrightSpring’s actual P/E of 91.07x sits well above the Fair Ratio of 32.56x, which suggests that the shares may be trading at a relatively high valuation on this measure.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your BrightSpring Health Services Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you link your view of BrightSpring’s story to specific forecasts for revenue, earnings and margins, turn that into a Fair Value, compare it to the current price to frame potential buy or sell decisions, and keep that view updated automatically as new news or earnings arrive. One investor might build a more cautious BrightSpring Narrative around a Fair Value near US$45.23 using assumptions closer to the bearish cohort, while another might build a more optimistic Narrative nearer US$59.97 using the higher growth and margin profile, giving you a clear, side by side sense of how different assumptions lead to different values.

For BrightSpring Health Services, we will make it straightforward for you by providing previews of two leading BrightSpring Health Services Narratives:

Start by asking which story fits better with how you see the business, then check whether that story lines up with the current share price.

🐂 BrightSpring Health Services Bull Case

Fair Value: US$59.97

Implied discount vs last close: about 21.2% below that fair value

Revenue growth assumption: 16.88% a year

• Focuses on specialty pharmacy growth and a pipeline of higher value therapies that support stronger revenue and margin potential.
• Assumes efficiency gains from automation, technology and acquisition integration can lift profitability and earnings over time.
• Builds in a future P/E of 25.1x on 2029 earnings, with earnings forecast at US$645.5m and a Fair Value of US$59.97.

🐻 BrightSpring Health Services Bear Case

Fair Value: US$45.23

Implied premium vs last close: about 4.5% above that fair value

Revenue growth assumption: 13.19% a year

• Highlights pressure from labor costs, reimbursement risk and ongoing integration of acquisitions that could weigh on margins.
• Assumes BrightSpring still grows earnings, but at a more measured pace, with earnings forecast at US$532.4m and a lower future P/E of 22.9x in 2029.
• Frames the shares closer to fairly priced, with Fair Value set at US$45.23 and less upside implied from the current share price.

If you want to see how other investors have joined the dots between these numbers and their own expectations, it is worth reading the full narratives, including how they handle risks, funding and longer term earnings power. To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for BrightSpring Health Services on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.

Do you think there’s more to the story for BrightSpring Health Services? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com